BAD Antibody / Bcl2-associated agonist of cell death

BAD antibody detects Bcl2-associated agonist of cell death, a pro-apoptotic member of the BCL2 protein family encoded by the BAD gene on chromosome 11q13.1. BAD is a cytoplasmic and mitochondrial-associated protein that regulates apoptosis by controlling mitochondrial outer membrane permeability. It is highly expressed in lymphoid tissues, liver, heart, and neurons, where it serves as a pivotal switch between cell survival and programmed cell death. BAD promotes apoptosis by binding to anti-apoptotic proteins BCL2 and BCL-XL, thereby freeing pro-apoptotic effectors such as BAX and BAK to induce cytochrome c release and caspase activation.

Under normal growth conditions, BAD remains phosphorylated and inactive, sequestered in the cytosol through association with 14-3-3 scaffold proteins. Upon cellular stress or growth factor deprivation, BAD becomes dephosphorylated by phosphatases such as PP2A, leading to its translocation to mitochondria and initiation of apoptosis. Functionally, BAD integrates signals from multiple pathways, including PI3K-AKT, MAPK, and cAMP-PKA, which regulate its phosphorylation state and apoptotic potential. Thus, BAD acts as a key convergence point for survival and death signals in diverse cell types.

Structurally, BAD contains BH3 (Bcl2 homology 3) domains essential for heterodimerization with other BCL2 family proteins. This domain mediates selective binding that determines the balance between apoptosis inhibition and activation. Post-translational modifications such as phosphorylation at serine residues (Ser112, Ser136, and Ser155) and dephosphorylation events fine-tune BAD activity in response to extracellular cues. The protein localizes to mitochondria during apoptosis induction, where it promotes permeabilization of the mitochondrial outer membrane and triggers the intrinsic apoptotic cascade.

Dysregulation of BAD expression or phosphorylation contributes to cancer, neurodegenerative diseases, and ischemic injury. Overactivation of BAD leads to neuronal loss in neurodegenerative conditions, while reduced activity supports tumor cell survival and resistance to therapy. In cancer research, BAD phosphorylation status serves as a marker for apoptosis sensitivity and therapeutic response. BAD also plays a metabolic role in glucose homeostasis, influencing insulin secretion and mitochondrial respiration in pancreatic beta cells.

BAD is a member of the BCL2 protein family, which governs mitochondrial apoptotic pathways by regulating membrane permeability and caspase activation. Pathway associations include the intrinsic apoptosis pathway and PI3K-AKT signaling, which modulate BAD phosphorylation and cellular survival. The protein's regulatory versatility makes it an important target in oncology, neurology, and metabolic research.

Immunohistochemical staining using BAD antibody reveals cytoplasmic and mitochondrial localization in apoptotic cells. The BAD antibody from